色又黄又爽18禁免费网站现观看,亚洲无码一,99国产精品国产精品九九,深夜福利久久久久久久久久久

掃碼關(guān)注公眾號(hào)           掃碼咨詢(xún)技術(shù)支持           掃碼咨詢(xún)技術(shù)服務(wù)
  
客服熱線(xiàn):400-901-9800  客服QQ:4009019800  技術(shù)答疑  技術(shù)支持  質(zhì)量反饋  人才招聘  關(guān)于我們  聯(lián)系我們
產(chǎn)品中心-北京博奧森生物技術(shù)有限公司
首頁(yè) > 產(chǎn)品中心 > 常用試劑 > 產(chǎn)品信息
DAPI (D-9106)  
訂購(gòu)熱線(xiàn):400-901-9800
訂購(gòu)郵箱:sales@bioss.com.cn
訂購(gòu)QQ:  400-901-9800
技術(shù)支持:techsupport@bioss.com.cn
說(shuō)明書(shū): 下載
10mg/600.00元
100mg/4500.00元
大包裝/詢(xún)價(jià)
產(chǎn)品編號(hào) D-9106
英文名稱(chēng) DAPI
中文名稱(chēng) 4',6-聯(lián)脒-2-苯基吲哚二鹽酸鹽
別    名 4',6-Diamidino-2-phenylindole, dihydrochloride; DAPI dihydrochloride; 2-(4-Amidinophenyl)-6-indolecarbamidine dihydrochloride; CAS:47165-04-8;   核酸染料;
Specific References  (33)     |     D-9106 has been referenced in 33 publications.
[IF=20.722] Meng Lin. et al. CRISPR-based in situ engineering tumor cells to reprogram macrophages for effective cancer immunotherapy. Nano Today. 2022 Feb;42:101359  Mouse.  
[IF=10.317] Qi Sun. et al. Phototherapy and anti-GITR antibody-based therapy synergistically reinvigorate immunogenic cell death and reject established cancers. Biomaterials. 2021 Feb;269:120648  
[IF=8.713] Zhao-Bo Luo. et al. Fecal transplant from myostatin deletion pigs positively impacts the gut-muscle axis. ELIFE. 2023; 12: e81858  
[IF=7.419] Honghua Yue. et al. Colchicine: Emerging therapeutic effects on atrial fibrillation by alleviating myocardial fibrosis in a rat model. BIOMED PHARMACOTHER. 2022 Oct;154:113573  Other ;  Other.  
[IF=7.328] Dongdong Yao. et al. Matrix stiffness regulates bone repair by modulating 12-lipoxygenase-mediated early inflammation. Mat Sci Eng C-Mater. 2021 Sep;128:112359  IF ;  Rat.  
[IF=6.575] Qingqing Liu. et al. A Synbiotic Ameliorates Con A-Induced Autoimmune Hepatitis in Mice Through Modulation of Gut Microbiota And Immune Imbalance. MOL NUTR FOOD RES. 2023 Jan;:2200428  
[IF=6.518] Yingjun Liu. et al. A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis. J Nanobiotechnol. 2021 Dec;19(1):1-17  Other ;  
[IF=6.208] Anqi Sun. et al. Serelaxin Alleviates Fibrosis in Thyroid-Associated Ophthalmopathy via the Notch Pathway. INT J MOL SCI. 2023 Jan;24(9):8356  
[IF=6.17] Lu Qi. et al. The inhibition of colorectal cancer growth by the natural product macrocarpal I. Free Radical Bio Med. 2021 Jan;162:383  
[IF=5.606] Luo Ping. et al. IL-37 inhibits M1-like macrophage activation to ameliorate temporomandibular joint inflammation through the NLRP3 pathway. Rheumatology. 2020 Oct;59(10):3070-3080  
[IF=5.344] Shenfei Zonget al. SERS-fluorescence-superresolution triple-mode nanoprobe based on surface enhanced Raman scattering and surface enhanced fluorescence. J Mater Chem B . 2020 Sep 23;8(36):8459-8466.  other ;  
[IF=5.215] Ling-Zhu Shi. et al. N-Butanol Extract of Glycyrrhizae Radix et Rhizoma Inhibits Dengue Virus through Targeting Envelope Protein. PHARMACEUTICALS-BASE. 2023 Feb;16(2):263  
[IF=5.195] Chunyang Tian. et al. Identification of an effective fraction from Ampelopsis radix with anti-dengue virus activities in vitro and in vivo. J ETHNOPHARMACOL. 2023 Mar;:116339  
[IF=5.058] Ping Hu. et al. The critical role of pancreatic stone protein/regenerating protein in sepsis-related multiorgan failure. FRONT MED-LAUSANNE. 2023; 10: 1172529  
[IF=4.979] Wanlin Xu. et al. Biocompatible Polyurethane Conduit Grafted with Vascular Endothelial Growth Factor-loaded Hydrogel Repairs the Peripheral Nerve Defect in Rats. 2021 Dec 04  IF ;  Rat.  
[IF=4.966] Ya‐Jing Yuan. et al. Shrm4 contributes to autophagy inhibition and neuroprotection following ischemic stroke by mediating GABAB receptor activation. Faseb J. 2020 Dec;34(12):15837-15848  IF ;  
[IF=4.939] Qi Wang. et al. MR/NIRF Dual-Mode Imaging of αvβ3 Integrin-Overexpressing Tumors Using a Lipopeptide-Based Contrast Agent. Mol Pharmaceut. 2021;XXXX(XXX):XXX-XXX  IF ;  Mouse.  
[IF=4.818] Zheng Mei. et al. Respiratory Syncytial Virus Nonstructural Protein 1 Promotes 5-Lipoxygenase via miR-19a-3p. J IMMUNOL RES. 2022;2022:4086710  
[IF=4.799] Ranran Zhang. et al. The Role of SREC-Ⅰ in Innate Immunity to Aspergillus fumigatus Keratitis. Invest Ophth Vis Sci. 2021 Jul;62(9):12-12  IF ;  Mouse.  
[IF=4.617] Wang, Yingli. et al. Ratiometric co-delivery of doxorubicin and paclitaxel prodrug by remote-loading liposomes for the treatment of triple-negative breast cancer. Drug Deliv Transl Re. 2022 Jan;:1-13  Other ;  Other.  
[IF=4.545] Ke Maet al. Neuroprotective effect of Hongjing I granules on erectile dysfunction in a rat model of bilateral cavernous nerve injury. Biomed Pharmacother . 2020 Oct;130:110405.  other ;  
[IF=4.145] Cuicui Hou. et al. Lysine demethylase 1B (Kdm1b) enhances somatic reprogramming through inducing pluripotent gene expression and promoting cell proliferation. EXP CELL RES. 2022 Nov;420:113339  Other ;  Other.  
[IF=3.969] Li, Yuanfang. et al. Weighted gene co-expression network indicates that the DYNLL2 is an important regulator of chicken breast muscle development and is regulated by miR-148a-3p. BMC GENOMICS. Bmc Genomics. 2022 Dec;23(1):1-12  Other ;  Other.  
[IF=3.946] Ziqi Chen. et al. Oxidative stress state inhibits exosome secretion of hPDLCs through a specific mechanism mediated by PRMT1. J PERIODONTAL RES. 2022 Sep;:  Other ;  Other.  
[IF=3.906] Zhenzhen Wen. et al. RORβ suppresses the stemness of gastric cancer cells by downregulating the activity of the Wnt signaling pathway. Oncol Rep. 2021 Aug;46(2):1-11  Other ;  Human.  
[IF=3.47] Zhaoxia Luo. et al. Effect of Electrical Stimulation of Cervical Sympathetic Ganglia on Intraocular Pressure Regulation According to Different Circadian Rhythms in Rats. Invest Ophth Vis Sci. 2020 Sep;61(11):40-40  IF ;  
[IF=3.423] Jing Zhao. et al. Oxysophoridine protects against cerebral ischemia/reperfusion injury via inhibition of TLR4/p38MAPK?mediated ferroptosis. MOL MED REP. 2023 Feb;27(2):1-11  
[IF=3.378] Liu, Can. et al. Deficiency of Lactoferrin aggravates lipopolysaccharide-induced acute inflammation via recruitment macrophage in mice. BIOMETALS. 2022 Jun;:1-14  
[IF=3.352] Yuanfang Li. et al. MiR-29b-1-5p regulates the proliferation and differentiation of chicken primary myoblasts and analysis of its effective targets. Poultry Sci. 2021 Nov;:101557  IF ;  Chicken.  
[IF=3.169] Hak Myong Choe. et al. Altered fibrinogen level and fibrin clot structure in myostatin homozygous mutant pig. 2022 Mar 13  Other ;  Other.  
保存條件 Store at -20℃, protect from light.
產(chǎn)品介紹 DAPI, or 4′,6-diamidino-2-phenylindole, is a fluorescent stain that binds strongly to adenine–thymine rich regions in DNA. It is used extensively in fluorescence microscopy. As DAPI can pass through an intact cell membrane, it can be used to stain both live and fixed cells, though it passes through the membrane less efficiently in live cells and therefore the effectiveness of the stain is lower.

DAPI基本信息:
  級(jí)別/純度:BR,98%
  CAS:28718-90-3
  分子式: C16H15N5·2HCl
  分子量: 350.25
  MDL: MFCD00012681

DAPI性質(zhì):
  1. 外觀:黃色粉末
  2. 純度:≥95% (HPLC)
  3. 產(chǎn)品描述:
  DAPI是一種可對(duì)DNA 染色的細(xì)胞核染色試劑,它在嵌入雙鏈DNA后釋放藍(lán)色熒光。DAPI常用于細(xì)胞凋亡檢測(cè),染色后用熒光顯微鏡觀察或流式細(xì)胞儀檢測(cè)。盡管DAPI不能通過(guò)活細(xì)胞膜,但卻能穿透擾亂的細(xì)胞膜而對(duì)核染色。DAPI具有很高的光漂白承受水平,能用來(lái)檢測(cè)酵母線(xiàn)粒體DNA,葉綠體DNA,病毒DNA,microplasm DNA以及染色體DNA。DAPI-DNA復(fù)合物的激發(fā)和發(fā)射波長(zhǎng)分別為360nm和460nm。
  4. 染色過(guò)程
  (1) 用1mL ddH2O將DAPI溶解,制得2.9mM的DAPI溶液(1mg DAPI/1mL H2O)。
  注:DAPI不能直接用PBS等緩沖溶液溶解,需要先用水將其溶解。
  (2) 取適量DAPI水溶液加到PBS中,制備成10~50μM的DAPI溶液。
  推薦以下PBS的配制方法:
  將8.0g NaCl、0.2g KCl、2.9g Na2HPO4·12H2O、0.2g KH2PO4 溶解于1L純水中。
  (3) 將1/10培養(yǎng)基體積的DAPI溶液加入到細(xì)胞培養(yǎng)基中。也可以用1/10濃度的DAPI緩沖液代替培養(yǎng)基。
  (4) 在37℃培養(yǎng)細(xì)胞10~20分鐘。
  (5) 用PBS或合適的緩沖液洗細(xì)胞兩次。
  (6) 用帶有360nm激發(fā)波長(zhǎng),460nm發(fā)射波長(zhǎng)的濾光片的熒光顯微鏡觀察細(xì)胞。

  儲(chǔ)存條件:-20℃干燥避光保存,有效期一年。

  注意事項(xiàng):
  DAPI對(duì)人體有一定刺激性,請(qǐng)注意適當(dāng)防護(hù)。
  熒光染料都存在淬滅的問(wèn)題,建議染色后盡量當(dāng)天完成檢測(cè)。
  為減緩熒光淬滅可以使用抗熒光淬滅封片液。
版權(quán)所有 2004-2026 北京博奧森生物技術(shù)有限公司
通過(guò)國(guó)際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書(shū)編號(hào): 00124Q34771R2M/1100
通過(guò)國(guó)際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書(shū)編號(hào): CQC24QY10047R0M/1100
京ICP備05066980號(hào)-1         京公網(wǎng)安備110107000727號(hào)